Eur Respir J 1996; 9: 356-363
Copyright © ERS Journals Ltd 1996
The role of thrombosis in severe pulmonary hypertension
A Chaouat,
E Weitzenblum,
and
T Higenbottam
Considering the important surface in pulmonary circulation where blood can interact with the endothelium, the maintenance of blood fluidity through the lung, by antithrombotic pathways and products of the endothelium, is essential. This function appears to be ineffective in primary pulmonary hypertension and in severe secondary pulmonary hypertension. Thrombotic lesions are frequently found in pulmonary arteries in these diseases. Thrombin activity appears to be increased in severe pulmonary hypertension. Antithrombotic pathway disorders may account for this abnormality, particularly in chronic thromboembolic pulmonary hypertension and primary pulmonary hypertension. Injured endothelium, a constant feature in severe pulmonary hypertension, either primary or secondary, enhances thrombus formation in pulmonary vessels. This is probably related to thrombomodulin and tissue factor imbalance, impairment of prostacyclin and nitric oxide release, as well as inefficiency of fibrinolysis. Moreover, platelets appear to be activated in the pulmonary circulation of these patients. They release several mediators acting on vascular tone and as mitogenic agents, and may also contribute to thrombin and clot generation. Long-term oral anticoagulant and continuous infusion of prostacyclin, treatments which impede thrombosis, are known to improve the survival rate in patients with primary pulmonary hypertension. These are the strongest arguments, so far, in favour of the role of thrombosis in severe pulmonary hypertension. However, we do not know whether these abnormalities result from a previous vascular injury or represent the primary disturbance.
This article has been cited by other articles:

|
 |

|
 |
 
B. Bakouboula, O. Morel, A. Faure, F. Zobairi, L. Jesel, A. Trinh, M. Zupan, M. Canuet, L. Grunebaum, A. Brunette, et al.
Procoagulant Membrane Microparticles Correlate with the Severity of Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med.,
March 1, 2008;
177(5):
536 - 543.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Ghofrani, R. Voswinckel, F. Reichenberger, N. Weissmann, R. T. Schermuly, W. Seeger, and F. Grimminger
Hypoxia- and non-hypoxia-related pulmonary hypertension - Established and new therapies
Cardiovasc Res,
October 1, 2006;
72(1):
30 - 40.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Galie and N. H. S. Kim
Pulmonary Microvascular Disease in Chronic Thromboembolic Pulmonary Hypertension
Proceedings of the ATS,
September 1, 2006;
3(7):
571 - 576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Rubin, M. M. Hoeper, W. Klepetko, N. Galie, I. M. Lang, and G. Simonneau
Current and Future Management of Chronic Thromboembolic Pulmonary Hypertension: From Diagnosis to Treatment Responses
Proceedings of the ATS,
September 1, 2006;
3(7):
601 - 607.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Peacock, G. Simonneau, and L. Rubin
Controversies, Uncertainties and Future Research on the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Proceedings of the ATS,
September 1, 2006;
3(7):
608 - 614.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Johnson, J. T. Granton, and S. Mehta
Thrombotic Arteriopathy and Anticoagulation in Pulmonary Hypertension.
Chest,
August 1, 2006;
130(2):
545 - 552.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. H. Caramuru, A. A. Lopes, N. Y. Maeda, V. D. Aiello, and C. C. Filho
Long-term Behavior of Endothelial and Coagulation Markers in Eisenmenger Syndrome
Clinical and Applied Thrombosis/Hemostasis,
April 1, 2006;
12(2):
175 - 183.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. BelAiba, T. Djordjevic, S. Bonello, F. Artunc, F. Lang, J. Hess, and A. Gorlach
The Serum- and Glucocorticoid-Inducible Kinase Sgk-1 Is Involved in Pulmonary Vascular Remodeling: Role in Redox-Sensitive Regulation of Tissue Factor by Thrombin
Circ. Res.,
March 31, 2006;
98(6):
828 - 836.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Hoeper, T. Kramm, H. Wilkens, C. Schulze, H. J. Schafers, T. Welte, and E. Mayer
Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension
Chest,
October 1, 2005;
128(4):
2363 - 2367.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Yaqub, K. G. Moder, and M. Q. Lacy
Severe, Reversible Pulmonary Hypertension in a Patient With Monoclonal Gammopathy and Features of Dermatomyositis
Mayo Clin. Proc.,
May 1, 2004;
79(5):
687 - 689.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Dartevelle, E. Fadel, S. Mussot, A. Chapelier, P. Herve, M. de Perrot, J. Cerrina, F.L. Ladurie, D. Lehouerou, M. Humbert, et al.
Chronic thromboembolic pulmonary hypertension
Eur. Respir. J.,
April 1, 2004;
23(4):
637 - 648.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. H. Caramuru, R. D. P. S. Soares, N. Y. Maeda, and A. A. Lopes
Hypoxia and Altered Platelet Behavior Influence von Willebrand Factor Multimeric Composition in Secondary Pulmonary Hypertension
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2003;
9(3):
251 - 258.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Ghofrani, R. T. Schermuly, F. Rose, R. Wiedemann, M. G. Kohstall, A. Kreckel, H. Olschewski, N. Weissmann, B. Enke, S. Ghofrani, et al.
Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension
Am. J. Respir. Crit. Care Med.,
April 15, 2003;
167(8):
1139 - 1141.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Shitrit, D. Bendayan, A. Bar-Gil-Shitrit, M. Huerta, B. Rudensky, G. Fink, and M. R. Kramer
Significance of a Plasma D-dimer Test in Patients With Primary Pulmonary Hypertension
Chest,
November 1, 2002;
122(5):
1674 - 1678.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Lopes, L. H. Caramuru, and N. Y. Maeda
Endothelial Dysfunction Associated with Chronic Intravascular Coagulation in Secondary Pulmonary Hypertension
Clinical and Applied Thrombosis/Hemostasis,
October 1, 2002;
8(4):
353 - 358.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Chatterjee, T. De Marco, and J. S. Alpert
Pulmonary Hypertension: Hemodynamic Diagnosis and Management
Arch Intern Med,
September 23, 2002;
162(17):
1925 - 1933.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A.T. Dinh-Xuan, M. Humbert, and R. Naeije
Severe pulmonary hypertension: walking through new paths to revisit an old field
Eur. Respir. J.,
September 1, 2002;
20(3):
509 - 510.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ueno, T. Miyauchi, S. Sakai, R. Yamauchi-Kohno, K. Goto, and I. Yamaguchi
A combination of oral endothelin-areceptor antagonist and oral prostacyclinanalogue is superior to each drug alone inameliorating pulmonary hypertension in rats
J. Am. Coll. Cardiol.,
July 3, 2002;
40(1):
175 - 181.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Beghetti, G. Reber, P. de Moerloose, L. Vadas, A. Chiappe, I. Spahr-Schopfer, and P.C. Rimensberger
Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation
Eur. Respir. J.,
March 1, 2002;
19(3):
518 - 524.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-C. Murciano, D. Harshaw, D. G. Neschis, L. Koniaris, K. Bdeir, S. Medinilla, A. B. Fisher, M. A. Golden, D. B. Cines, M. T. Nakada, et al.
Platelets inhibit the lysis of pulmonary microemboli
Am J Physiol Lung Cell Mol Physiol,
March 1, 2002;
282(3):
L529 - L539.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G Espinosa, R Cervera, J Font, and R A Asherson
The lung in the antiphospholipid syndrome
Ann Rheum Dis,
March 1, 2002;
61(3):
195 - 198.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Edelberg, P. D. Christie, and R. D. Rosenberg
Regulation of Vascular Bed-Specific Prothrombotic Potential
Circ. Res.,
July 20, 2001;
89(2):
117 - 124.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kereveur, J. Callebert, M. Humbert, P. Herve, G. Simonneau, J.-M. Launay, and L. Drouet
High Plasma Serotonin Levels in Primary Pulmonary Hypertension : Effect of Long-Term Epoprostenol (Prostacyclin) Therapy
Arterioscler Thromb Vasc Biol,
October 1, 2000;
20(10):
2233 - 2239.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J Stratton, L. Pompon, J. G Coghlan, J. D Pearson, and C. M Black
Soluble thrombomodulin concentration is raised in scleroderma associated pulmonary hypertension
Ann Rheum Dis,
February 1, 2000;
59(2):
132 - 134.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A. Russo, M. De Luca, C. Vigna, Vincenzo De Rito, M. Pacilli, A. Lombardo, M. Armillotta, R. Fanelli, and F. Loperfido
Central Pulmonary Artery Lesions in Chronic Obstructive Pulmonary Disease : A Transesophageal Echocardiography Study
Circulation,
October 26, 1999;
100(17):
1808 - 1815.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. R. Pendurthi, L. V. M. Rao, J. T. Williams, and S. Idell
Regulation of Tissue Factor Pathway Inhibitor Expression in Smooth Muscle Cells
Blood,
July 15, 1999;
94(2):
579 - 586.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Egermayer, G I. Town, and A. J Peacock
Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension
Thorax,
February 1, 1999;
54(2):
161 - 168.
[Full Text]
|
 |
|

|
 |

|
 |
 
Z. Nong, M. Hoylaerts, N. Van Pelt, D. Collen, and S. Janssens
Nitric Oxide Inhalation Inhibits Platelet Aggregation and Platelet-Mediated Pulmonary Thrombosis in Rats
Circ. Res.,
November 19, 1997;
81(5):
865 - 869.
[Abstract]
[Full Text]
|
 |
|
Copyright © 1996 by the European Respiratory Society.
|